{"id":6932,"date":"2024-03-20T09:54:00","date_gmt":"2024-03-20T09:54:00","guid":{"rendered":"https:\/\/ibsal.es\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/"},"modified":"2025-03-10T18:17:35","modified_gmt":"2025-03-10T18:17:35","slug":"ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies","status":"publish","type":"post","link":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/","title":{"rendered":"IBSAL, in a European consortium endowed with 2.5 million to promote the manufacture of cell therapies"},"content":{"rendered":"\n<p><strong>The &#8216;Penphomet&#8217; project, led by the technology company Trince and with the participation of the NecstGen laboratory, has been chosen by the European Innovation Council from among 257 applications to make cell therapy more accessible to patients.<\/strong><\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><strong>This initiative &#8220;opens the possibility of exploring a new strategy for cell modification that could be enormously attractive for the next generation of advanced therapy drugs,&#8221; says Ferm\u00edn S\u00e1nchez-Guijo, principal investigator of the Institute.<\/strong><\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>After a rigorous selection process by a panel of<a href=\"https:\/\/trincebio.com\/\"> Trince<\/a> experts, NecstGen and the <a href=\"https:\/\/ibsal.es\/en\/\">Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca<\/a> (IBSAL) are proud to announce that their <strong> <em>Penphomet<\/em> project has been selected by the European Innovation Council (EIC) for a major grant of 2.5 million euros<\/strong>. Out of 257 eligible proposals, <em>Penphomet<\/em> is one of the 27 that have been awarded. Led by Trince, the consortium aims to revolutionize the manufacture of cell therapies by integrating nanotechnology, optics and microfluidics.  <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>Cell therapy has shown <strong>promising results in cancer treatment<\/strong>, specifically using patient-derived cells, such as T cells and mesenchymal stromal cells (MSCs) that have been genetically modified to effectively target cancer cells.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>The main objective of the <em>Penphomet <\/em>project is to <strong>develop a safer non-viral method<\/strong> for cell engineering with minimal impact on cell functionality and phenotype. The goal is to <strong>significantly reduce the costs associated with the manufacture of cell therapies<\/strong>. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>Over three years, the project aims to deliver a <strong>fully automated, high-performance system<\/strong> that can be installed in centralized cell production facilities or integrated into point-of-care cell manufacturing equipment.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>&#8220;We are grateful for the EIC&#8217;s support in funding the <strong>Penphomet<\/strong> project. It demonstrates that our innovative technology is addressing a crucial gap in the field of cell therapy,&#8221; asserts <strong>Philip Mathuis<\/strong>, CEO of Trince. &#8220;Together with our partners NecstGenh the IBSAL, we are committed to advancing the manufacturing of cell therapies, which will ultimately benefit patients and healthcare systems.&#8221;  <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>&#8220;NecstGen is proud to be part of the <em>Penphomet<\/em> consortium <em>,<\/em> which supports the development of Trince&#8217;s innovative technology. Non-viral methods for cell engineering represent a potentially cost-saving route to cell engineering therapies. And promoting their use is important to the field of cell and gene therapy and to NecstGen&#8217;s mission of enabling patient access,&#8221; said <strong>Paul Bilars<\/strong>, CEO of NecstGen.  <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>&#8220;For the IBSAL, and its participating entities (the University Hospital, the University of Salamanca and the CSIC) the <strong>Penphomet<\/strong> project opens the possibility of exploring a new strategy of cell modification that can be enormously attractive for the next generation of advanced therapy drugs, and we are very excited to be part of this initiative,&#8221; says Prof. Ferm\u00edn S\u00e1nchez-Guijo, principal investigator of the IBSAL in this initiative.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/ibsal.es\/images\/Foto_Prof._F._Sanchez-Guijo.jpg\" alt=\"Photo_Prof._F._Sanchez-Guijo.jpg\"\/><\/figure>\n\n<p>Prof. Ferm\u00edn S\u00e1nchez-Guijo, coordinator of the Gene, Cell and Transplant Therapy Area of the Institute of Biomedical Research of Salamanca (IBSAL).<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>The <strong>Penphomet <\/strong>project represents a significant advance in improving the accessibility and affordability of cell therapies, with the potential to have a far-reaching impact on the treatment of cancer and other diseases that are candidates for cell and gene therapy strategies.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<h4 class=\"wp-block-heading\" id=\"h-el-ibsal\"><strong>The IBSAL<\/strong><\/h4>\n\n<p>The Institute of Biomedical Research of Salamanca (IBSAL) was established on March 21, 2011 through an agreement signed by the Ministry of Health of the Regional Government of Castilla y Le\u00f3n and the University of Salamanca, which was joined in February 2012 by the Spanish National Research Council (CSIC). It integrates and coordinates the biosanitary research carried out at the University Hospital of Salamanca, the Primary Care Management of Salamanca and the biosanitary area of the University of Salamanca, including the Institute of Neurosciences of Castilla y Le\u00f3n and the Institute of Molecular and Cellular Biology of Cancer. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>Its scientific activity is structured in six areas, with a total of 78 research groups: Cancer (22 groups); Cardiovascular (8); Neurosciences (12); Infectious, Inflammatory and Metabolic Diseases (17); Gene and Cell Therapy and Transplants (5) and Primary Care, Public Health and Pharmacology (14).<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><strong>More information and contact:<\/strong><br\/><strong><a href=\"mailto:comunicacion@ibsal.es\"><\/a><a href=\"mailto:comunicacion@ibsal.es\">comunicacion@ibsal.es<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The &#8216;Penphomet&#8217; project, led by the technology company Trince and with the participation of the NecstGen laboratory, has been chosen by the European Innovation Council from among 257 applications to [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":6531,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[238],"tags":[255],"class_list":["post-6932","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-cell-therapy"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.12 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>IBSAL, in a European consortium endowed with 2.5 million to promote the manufacture of cell therapies | IBSAL<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IBSAL, in a European consortium endowed with 2.5 million to promote the manufacture of cell therapies\" \/>\n<meta property=\"og:description\" content=\"The &#8216;Penphomet&#8217; project, led by the technology company Trince and with the participation of the NecstGen laboratory, has been chosen by the European Innovation Council from among 257 applications to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"IBSAL\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-20T09:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-10T18:17:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/02\/CEREB_-71-e1738922446154.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1402\" \/>\n\t<meta property=\"og:image:height\" content=\"790\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sergi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sergi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/\"},\"author\":{\"name\":\"Sergi\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\"},\"headline\":\"IBSAL, in a European consortium endowed with 2.5 million to promote the manufacture of cell therapies\",\"datePublished\":\"2024-03-20T09:54:00+00:00\",\"dateModified\":\"2025-03-10T18:17:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/\"},\"wordCount\":665,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/CEREB_-71-e1738922446154.jpg\",\"keywords\":[\"Cell therapy\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/\",\"url\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/\",\"name\":\"IBSAL, in a European consortium endowed with 2.5 million to promote the manufacture of cell therapies | IBSAL\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/CEREB_-71-e1738922446154.jpg\",\"datePublished\":\"2024-03-20T09:54:00+00:00\",\"dateModified\":\"2025-03-10T18:17:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/CEREB_-71-e1738922446154.jpg\",\"contentUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/CEREB_-71-e1738922446154.jpg\",\"width\":1402,\"height\":790},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibsal.es\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IBSAL, in a European consortium endowed with 2.5 million to promote the manufacture of cell therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/ibsal.es\\\/en\\\/\",\"name\":\"IBSAL\",\"description\":\"Benchmarks in translational research in biomedicine in Castilla y Le\u00f3n\",\"alternateName\":\"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibsal.es\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\",\"name\":\"Sergi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"caption\":\"Sergi\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IBSAL, in a European consortium endowed with 2.5 million to promote the manufacture of cell therapies | IBSAL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/","og_locale":"en_US","og_type":"article","og_title":"IBSAL, in a European consortium endowed with 2.5 million to promote the manufacture of cell therapies","og_description":"The &#8216;Penphomet&#8217; project, led by the technology company Trince and with the participation of the NecstGen laboratory, has been chosen by the European Innovation Council from among 257 applications to [&hellip;]","og_url":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/","og_site_name":"IBSAL","article_published_time":"2024-03-20T09:54:00+00:00","article_modified_time":"2025-03-10T18:17:35+00:00","og_image":[{"width":1402,"height":790,"url":"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/02\/CEREB_-71-e1738922446154.jpg","type":"image\/jpeg"}],"author":"Sergi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sergi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/#article","isPartOf":{"@id":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/"},"author":{"name":"Sergi","@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97"},"headline":"IBSAL, in a European consortium endowed with 2.5 million to promote the manufacture of cell therapies","datePublished":"2024-03-20T09:54:00+00:00","dateModified":"2025-03-10T18:17:35+00:00","mainEntityOfPage":{"@id":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/"},"wordCount":665,"commentCount":0,"image":{"@id":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/02\/CEREB_-71-e1738922446154.jpg","keywords":["Cell therapy"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/","url":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/","name":"IBSAL, in a European consortium endowed with 2.5 million to promote the manufacture of cell therapies | IBSAL","isPartOf":{"@id":"https:\/\/ibsal.es\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/#primaryimage"},"image":{"@id":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/02\/CEREB_-71-e1738922446154.jpg","datePublished":"2024-03-20T09:54:00+00:00","dateModified":"2025-03-10T18:17:35+00:00","author":{"@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97"},"breadcrumb":{"@id":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/#primaryimage","url":"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/02\/CEREB_-71-e1738922446154.jpg","contentUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/02\/CEREB_-71-e1738922446154.jpg","width":1402,"height":790},{"@type":"BreadcrumbList","@id":"https:\/\/ibsal.es\/en\/ibsal-in-a-european-consortium-endowed-with-2-5-million-to-promote-the-manufacture-of-cell-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibsal.es\/en\/"},{"@type":"ListItem","position":2,"name":"IBSAL, in a European consortium endowed with 2.5 million to promote the manufacture of cell therapies"}]},{"@type":"WebSite","@id":"https:\/\/ibsal.es\/en\/#website","url":"https:\/\/ibsal.es\/en\/","name":"IBSAL","description":"Benchmarks in translational research in biomedicine in Castilla y Le\u00f3n","alternateName":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibsal.es\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97","name":"Sergi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","caption":"Sergi"}}]}},"_links":{"self":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts\/6932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/comments?post=6932"}],"version-history":[{"count":0,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts\/6932\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/media\/6531"}],"wp:attachment":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/media?parent=6932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/categories?post=6932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/tags?post=6932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}